Why US Biotech Firm Picks Hong Kong Listing Before Wall Street

Have you ever wondered what makes a promising American biotech company turn away from the familiar lights of Wall Street and instead set its sights on listing halfway around the world? It’s not every day that a San Diego-based innovator in regenerative and genetic medicines decides to make Hong Kong its primary public debut. Yet that’s exactly the path Axiom Biosciences is charting, with plans for a 2027 listing there followed by a secondary US appearance in 2029.

This move feels bold, almost contrarian in an industry where the United States has long been the undisputed king of capital raising. But dig a little deeper, and it starts to make a lot of sense. The global biotech landscape is evolving rapidly, and savvy founders are looking beyond traditional borders to find the right mix of investors, partners, and growth opportunities.

A Contrarian Bet on Asian Opportunities

In my experience following these trends, timing and location in public markets can be just as crucial as the science itself. For Axiom, the decision reflects a calculated strategy to tap into Hong Kong’s expanding role as a biotech hub. The city has been steadily building its credentials, attracting listings that benefit from proximity to China’s massive pharmaceutical ecosystem and a growing pool of dedicated investors.

Remo Moomiaie-Qajar, the company’s founder and CEO, has been vocal about the funding challenges facing many biotech ventures today. As clinical programs advance and costs climb, the number of venture firms able to write those big checks shrinks dramatically. Public markets, he argues, offer a vital alternative path. And while the US remains incredibly deep, Hong Kong provides something different: direct access to partners who can accelerate development in ways that purely domestic plays might struggle to match.

The Science Driving the Strategy

Axiom focuses on regenerative and genetic medicines, areas with enormous potential but also significant hurdles in getting therapies to patients quickly. One of their key programs involves a therapy for newborns suffering severe brain injuries, developed in collaboration with a South Korean partner. This work has already earned rare pediatric disease designations from US regulators, and early trials have wrapped up in Asia.

Why does this matter for their listing choice? Because Asia isn’t just about capital. It’s about speed. The region offers large patient populations concentrated in major medical centers, which can dramatically shorten recruitment timelines for clinical studies. Lower operational costs combined with skilled talent pools make it an attractive environment for scaling the “1-to-100” phase of bringing innovations to market.

The most important science is still being built in the United States, but the funding mechanisms haven’t always kept up with the pace of discovery.

– Biotech industry observer

I’ve seen this tension play out repeatedly. American labs excel at those foundational breakthroughs, the “0-to-1” moments that redefine possibilities. Yet turning those discoveries into widely available treatments requires efficient manufacturing, rapid trial execution, and deep commercial insights. That’s where strategic international moves can provide an edge.

Hong Kong’s Rising Appeal for Life Sciences

Hong Kong has worked hard to position itself as more than just a financial center. Reforms in recent years have streamlined the IPO process for biotech companies, and the exchange now boasts over 70 listings in the sector. The Hang Seng Biotech Index has shown impressive performance, outpacing some US benchmarks during certain periods.

Local investors there often look for clear pathways to collaboration with Chinese pharmaceutical companies. This can mean faster co-development, manufacturing partnerships, or market access across Asia. For a company like Axiom, such connections aren’t theoretical advantages – they could translate into real acceleration for programs targeting brain injuries and stroke recovery.

• Proximity to manufacturing hubs that reduce costs
• Access to large, diverse patient cohorts for trials
• Growing base of sophisticated biotech-focused capital
• Regulatory environment that values innovation with practical milestones

Of course, it’s not all smooth sailing. Hong Kong maintains stricter listing requirements than some US exchanges, demanding demonstrated research progress and a core product beyond early concepts. This maturity, however, may signal a more stable ecosystem less prone to wild speculation.

Comparing Capital Markets: Depth Versus Reach

The United States undeniably holds the crown for sheer depth of institutional biotech investment. Major funds, specialized analysts, and a culture comfortable with high-risk, high-reward science create an unparalleled environment for raising capital. Many of the world’s most competitive assets still flock there for good reason.

Yet global dynamics are shifting. Chinese biotech has advanced considerably in clinical development, supply chain efficiency, and implementation speed. Government support for the sector, combined with talent returning from overseas training, has created a formidable player. While the US leads in cutting-edge discovery, other regions are closing gaps in scaling and commercialization.

This reality creates opportunities for hybrid strategies. A primary Hong Kong listing doesn’t mean abandoning American markets – it means building a stronger foundation first. Axiom’s plan for a secondary US listing later acknowledges the ongoing importance of US capital while prioritizing Asian operational advantages early on.

Challenges and Risks in Cross-Border Listings

No strategic pivot comes without potential downsides. Valuations in Hong Kong have historically run lower than on Nasdaq, which could affect initial capital raised. Investor preferences there often tilt toward companies with strong China ties, potentially requiring extra effort to highlight global assets.

Review timelines can stretch as applications increase, and cultural nuances in investor relations matter greatly. Axiom will need to clearly communicate its value proposition to an audience that might evaluate opportunities through a different lens than Silicon Valley venture partners.

Local investors tend to back assets where they see clear opportunities for collaboration within the region.

Geopolitical considerations add another layer. Tensions between the US and China have led to increased scrutiny of biotech supply chains and partnerships. Companies must navigate export controls, security reviews, and shifting regulatory sands carefully. Axiom’s focus on regenerative therapies for pediatric and adult neurological conditions positions it in a therapeutic area with broad humanitarian appeal, which may help transcend some of these frictions.

The Broader Biotech Fundraising Environment

Let’s step back for a moment. The entire industry faces pressure. After years of easy capital, many firms now struggle as later-stage financing rounds require larger checks that fewer investors can or will provide. Clinical costs continue climbing while success rates remain challenging.

In this context, creative listing strategies become survival tools rather than luxuries. Recent US biotech IPOs have shown strength, with some newcomers posting impressive first-day gains. Yet not every company fits the profile that excites domestic public investors immediately. For those with strong Asian scientific or commercial synergies, looking abroad first can unlock different types of support.

This isn’t about choosing sides. It’s about recognizing that different markets excel at different parts of the value chain. Smart management teams align their financing with their operational realities.

What This Means for the Industry

Axiom’s decision could signal a new chapter for US biotechs comfortable operating across borders. As China’s capabilities grow in “1-to-100” execution, more companies may explore similar dual-market approaches. Success here might encourage others to think more creatively about primary listing venues.

However, purely American stories without clear regional ties will likely continue favoring US exchanges. The depth of specialized knowledge among US investors remains unmatched for evaluating novel biology and platform technologies.

Perhaps the most interesting aspect is how this reflects maturing global biotech ecosystems. No longer is the choice binary between staying home or going to the deepest pool. Companies can now design financing strategies that match their specific scientific and commercial journeys.

Looking Ahead for Regenerative Medicine

The therapeutic focus areas matter tremendously. Brain injuries in newborns and stroke recovery represent areas of high unmet need with limited existing options. Regenerative approaches could transform outcomes where current treatments fall short. Speeding development through Asian infrastructure while maintaining rigorous standards could benefit patients worldwide.

I’ve always believed that the best innovations succeed when science, capital, and operational excellence align. Axiom seems to be engineering precisely that alignment by leveraging Hong Kong’s position as a bridge between East and West.

1. Secure primary listing and regional partnerships
2. Advance clinical programs with Asian efficiency
3. Build track record for secondary US listing
4. Scale globally from a position of demonstrated progress

This sequenced approach minimizes some risks while maximizing access to complementary strengths. It acknowledges that breakthroughs need more than brilliant ideas – they need pathways to patients.

Investment Implications and Considerations

For investors, stories like this highlight the importance of looking beyond traditional US-centric portfolios. While domestic exchanges offer familiarity, global exposure in biotech can provide diversification and exposure to different growth drivers. However, additional risks around currency, regulation, and geopolitics require careful evaluation.

Those following the sector should watch how Axiom executes its plan. Successful navigation of the Hong Kong listing process and subsequent clinical progress could validate the strategy and open doors for similar approaches. Failure, conversely, might reinforce preferences for US-first strategies.

Either way, the mere fact of this decision underscores how interconnected the global life sciences industry has become. Capital, talent, and patients increasingly flow across borders, rewarding companies that build truly international capabilities.

The Human Element Behind Corporate Strategy

Behind every bold listing decision stands a team of scientists, executives, and advisors who believe their approach can make a difference. For Axiom, the motivation appears rooted in urgency – the need to move promising therapies forward as quickly as responsibly possible. When no good options exist for devastating conditions, every month saved in development carries profound weight.

This human dimension often gets lost in discussions of markets and valuations. Yet it’s what ultimately drives innovation. Founders who balance scientific passion with strategic pragmatism tend to create lasting value.

Broader Economic and Policy Context

Governments worldwide recognize biotechnology as a strategic priority. Beijing has invested heavily in research, regulation, and talent attraction for decades. Washington continues pushing to maintain leadership through public-private coordination and targeted support.

The resulting competition benefits the field overall, even as it creates navigation challenges for individual companies. Those able to access the best of multiple ecosystems may emerge strongest.

Axiom’s story illustrates how individual firms can thread this needle. By choosing Hong Kong first, they’re not rejecting American strengths but supplementing them with Asian advantages at the right development stage.

Key Takeaways for Biotech Entrepreneurs

If you’re building in this space, consider these lessons:

• Map your operational needs against global market strengths
• Think strategically about listing timing and sequencing
• Build genuine partnerships rather than just raising capital
• Stay flexible as geopolitical and market conditions evolve
• Never lose sight of the patients waiting for solutions

The traditional playbook still works for many, but rigid adherence to old patterns may limit opportunities in an increasingly multipolar world.

As someone who tracks these developments, I find Axiom’s approach refreshing. It demonstrates confidence in their science and willingness to challenge conventional wisdom. In biotech, where breakthroughs often require seeing possibilities others miss, that mindset serves companies well.

The coming years will reveal whether this contrarian path pays off. But regardless of outcome, it adds an important data point to conversations about how the next generation of life science companies will fund and scale their ambitions. The old model of US-only thinking is giving way to more nuanced, globally informed strategies.

And that, ultimately, should accelerate the pace at which promising therapies reach those who need them most. In the end, that’s what really matters.

Expanding on the regulatory landscape, Hong Kong’s requirements push companies to demonstrate meaningful progress before going public. This can filter for more mature programs but also rewards teams that have built robust data packages early. For regenerative medicine, where mechanisms can be complex, this extra scrutiny may actually build investor confidence over time.

Meanwhile, the US system allows earlier listings in some cases, enabling companies to tap public markets while still in early clinical stages. Both approaches have merits depending on the asset, team, and market conditions. Axiom appears to have evaluated their specific situation and chosen the path that best aligns with their partnership strategy and development timeline.

Clinical trial logistics represent another crucial factor. Recruiting for rare pediatric conditions demands specialized centers and motivated families. Asia’s healthcare infrastructure, with major hospitals serving large populations, offers efficiencies that can compress timelines significantly. When every week counts for patients facing life-altering injuries, these advantages become compelling.

Manufacturing scale-up for cell and gene therapies also benefits from regional capabilities. Lower costs combined with improving quality standards create attractive options for companies planning commercial production. Forward-thinking management teams factor these elements into financing decisions rather than treating them as afterthoughts.

Investor education will play a key role in Axiom’s success. They must effectively communicate their dual-market strategy, highlighting how Hong Kong listing enhances rather than dilutes their US potential. Transparency about partnership terms, regulatory pathways, and risk management will be essential.

The biotech sector’s cyclical nature means windows of opportunity open and close. By preparing for a 2027 Hong Kong debut, Axiom positions itself to capitalize on current positive sentiment in Asian markets while building toward US re-engagement when their story has more clinical data to tell.

This patience could prove wise. Companies that rush to public markets before establishing key proof points sometimes struggle with volatility. A more measured international approach might provide stability and strategic flexibility.

Looking even further ahead, successful execution could inspire other US biotechs with strong Asian scientific collaborations to consider similar paths. The trend toward globalization in biotech isn’t reversing anytime soon. Understanding and leveraging it strategically will distinguish leaders from followers.

In conclusion, Axiom Biosciences’ decision represents more than a simple listing choice. It embodies a sophisticated understanding of how global capabilities can combine to advance medical innovation faster and more effectively. As the industry continues maturing, expect to see more creative cross-border strategies that challenge traditional assumptions about where and how biotech companies should go public.

The intersection of cutting-edge American science with Asian execution excellence could unlock tremendous value for patients, investors, and society. Watching how this particular story unfolds will offer valuable insights into the future shape of global biotech development.